New Market Report: PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023

Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression. The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market. The glaucoma market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aerie's Rhopressa, Bausch & Lomb's Vesneo (latanoprost bunod), and Inotek's trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma market.

Full Report Details at
- http://www.fastmr.com/prod/1038176_pharmapoint_glaucoma_global.aspx?afid=301

Highlights

Key Questions Answered

* The glaucoma market has been dominated by prostaglandin analogue (PGA) drugs in the last decade. New classes of drugs are anticipated the reach the market within the forecast period. How will these change the position the PGA drugs hold during the forecast period? Will these drugs maintain their market dominance in 2023?
* The current late stage glaucoma pipeline is varied, with first-in-class drugs in development with innovative modes of action. Which of these will have the biggest impact on the market? What strategies are developers undertaking to penetrate this crowded and highly generic market? Will these fulfil any unmet needs?
* Population aging is occurring in almost all countries worldwide, particularly in the 7MM. This is expected to have a significant impact on the prevalence of age-related diseases such as glaucoma. How will epidemiological changes impact the growth of the future market?

Key Findings

* The main driver of growth in the glaucoma market will be the introduction of first-in-class drugs over the forecast period. The launch of three first-in-class therapies will grow this market. New fixed-dose drugs entering the 7MM will also act as a stimulant for growth.
* The biggest barrier for growth in the glaucoma market will be the increasing use of generic latanoprost across the 7MM. The low cost of this therapy will increase the pressure on new drugs hoping to enter these markets to show drug cost-effectivness. This is likely to have a negative impact on these markets, as regulatory bodies are adopting stricter criterial for new drug approvals and reimbursement listing.
* The largest unmet needs mainly reflect the notorious problem of poor patient adherence to therapy. Simplifying dosing regimens is an important consideration for companies developing drugs to treat these patients.

Scope

* Overview of glaucoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2023